Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies.
Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies.
复制标题
DOI：
10.3389/fimmu.2014.00341
复制
发表时间：
2014
影响因子：
7.3
通讯作者：
Benencia F
中科院分区：
文献类型：
--
作者：
Muccioli M;Benencia F
在过去的十年中，Toll样受体(TLR)信号在卵巢癌(OC)的进展中起着重要的作用。有趣的是，免疫细胞中TLR的激活可以帮助激活抗肿瘤反应，而肿瘤细胞中的TLR信号本身通常与促癌炎症有关。例如，已有研究表明，树突状细胞中TLR的激活可以导致更有效的抗原呈递给T细胞，从而有利于肿瘤的根除。然而，OC细胞中TLR的异常表达与更具侵袭性的疾病有关(可能是由于亲肿瘤的白细胞重新聚集到肿瘤部位)，也与主流化疗的耐药性有关。在不同细胞类型的肿瘤微环境中，TLR活性的微妙平衡有助于形成炎症轮廓和肿瘤生长或消退的结果。随着进一步的研究，TLRs的特异性激活或抑制可能被利用来为一些OC患者提供传统化疗的新的免疫疗法或佐剂。在此，我们回顾了有关TLR通路治疗OC的基础研究和翻译研究的最新文献。
In the last decade, it has become apparent that toll-like receptor (TLR) signaling can play an important role in ovarian cancer (OC) progression. Interestingly, TLR activation in immune cells can help activate an anti-tumor response, while TLR signaling in tumor cells themselves is often associated with cancer-promoting inflammation. For example, it has been shown that TLR activation in dendritic cells can result in more effective antigen presentation to T cells, thereby favoring tumor eradication. However, aberrant TLR expression in OC cells is associated with more aggressive disease (likely due to recruitment of pro-tumoral leukocytes to the tumor site) and has also been implicated in resistance to mainstream chemotherapy. The delicate balance of TLR activation in the tumor microenvironment in different cell types altogether help shape the inflammatory profile and outcome of tumor growth or regression. With further studies, specific activation or repression of TLRs may be harnessed to offer novel immunotherapies or adjuvants to traditional chemotherapy for some OC patients. Herewith, we review recent literature on basic and translational research concerning therapeutic targeting of TLR pathways for the treatment of OC.
登录
查看更多内容
DOI：
10.1038/nrc2644
发表时间：
2009-06
期刊：
Nature reviews. Cancer
影响因子：
--
作者：
通讯作者：
--
影响因子：
4.7
作者：
Benencia F;Muccioli M;Alnaeeli M
通讯作者：
Alnaeeli M
影响因子：
20.3
作者：
Conejo-Garcia, JR;Buckanovich, RJ;Coukos, G
通讯作者：
Coukos, G
影响因子：
11.2
作者：
Huang, B;Zhao, J;Xiong, HB
通讯作者：
Xiong, HB
Toll 样受体 7 激动剂以延长给药方案皮下注射，用于治疗经过严格预处理的复发性乳腺癌、卵巢癌和宫颈癌。
DOI：
10.1007/s00262-010-0914-1
发表时间：
2010-12
期刊：
Cancer immunology, immunotherapy : CII
影响因子：
--
作者：
Geller MA;Cooley S;Argenta PA;Downs LS;Carson LF;Judson PL;Ghebre R;Weigel B;Panoskaltsis-Mortari A;Curtsinger J;Miller JS
通讯作者：
Miller JS